Bruce van Natta
Indianapolis, INNPI 1881652444
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.1%), other and speaking fees — rather than concentrated in one kind of arrangement. Davol Inc. accounts for 84.8% of it on its own, with 15 other manufacturers making up the rest.
Across 216 payments — averaging $2112.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$387K
- Tepha Inc$53K
- C. R. Bard, Inc. & Subsidiaries$8K
- Sientra, Inc.$2K
- AbbVie$2K
- Motiva USA, LLC$1K
- plus $3K from 10 others
Across 19 payments — averaging $6486.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tepha Inc$93K
- Davol Inc.$17K
- Motiva USA, LLC$13K
What the payments were for
- Consulting fees$210,31146%
- Speaking & faculty fees$32,4657%
- Travel & lodging$21,0375%
- Food & beverage$8,4452%
- Other$183,97740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 88 | $387,109 |
| Tepha Inc | 24 | $53,339 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $7,670 |
| Sientra, Inc. | 20 | $2,436 |
| AbbVie(2 entities) | 32 | $1,526 |
| Motiva USA, LLC | 16 | $1,248 |
| BD | 7 | $1,046 |
| Bard Peripheral Vascular, Inc. | 11 | $805 |
| Integra Lifesciences Corporation | 4 | $711 |
| Medtronic | 3 | $158 |
| Novo Nordisk | 2 | $47 |
| Mentor Worldwide LLC | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Eagle Pharmaceuticals, Inc. | 1 | $24 |
| KCI USA, Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 27 | $105 |
| Ondansetron OdtOndansetron | 17 | $63 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.